Audio conference to be held October 3, 2013
Section 101 of the patent statutes defines the conditions for patent-eligible subject matter. Historically, Section 101 issues have not been predominant in the life sciences. However, two recent Supreme Court cases have challenged those assumptions and clarified what scientific discoveries are eligible for patentability under Section 101. For example, Mayo v. Prometheus involved an analysis of patentability of tests applying correlations between drugs and metabolites. Another recent case, Association for Molecular Pathology v. Myriad Genetics, involved patentability of isolated DNA sequences. In this audio conference presentation, the speaker discusses examples of both patent-eligible and non-patent eligible subject matter, and discusses strategies and implications for life sciences companies in the wake of these recent landmark Supreme Court cases.
This audio conference covers:
- An overview of Section 101 and its importance to life sciences companies
- Recent Supreme Court cases impacting life sciences companies
- Why law of nature and purification or isolation of a naturally occurring material does not warrant patentability
- When structural modifications to a naturally occurring material might make it patent-eligible
- Why Section 101 is only a bare litmus for patentability; novelty and obviousness issues must be considered
About the speaker:
Jay Pattumudi is an experienced patent attorney with a graduate degree in biochemistry and molecular biology. His experience includes drafting patent applications as well as prosecuting those applications in such technological fields including biotechnology, chemical and pharmaceutical areas, mechanical matters, medical devices, and materials science. In addition, he has drafted opinions relating to non-infringement and invalidity in many of those fields. He has worked for a large general practice firm as well as patent boutique firms, including a life sciences patent boutique firm. Pattumudi has represented large companies, university start-ups, clients of foreign firms, and individuals.
More information here: http://www.fxconferences.com/Product2.aspx?ProductId=1550&CategoryId=1